Shirin David

Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer

Retrieved on: 
수요일, 2월 21, 2024
FDA, Health, General Health, Pharmaceutical, Cardiology, Biotechnology, Division, Multimedia, Unstable angina, MD, Drug development, Risk, Safety, Therapy, Nephrology, Disease, Percutaneous coronary intervention, Patient, Acute kidney injury, AKI, Shirin David, Trimetazidine, IND, Mortality, Circulatory system, PCI, Pharmaceutical industry

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.

Key Points: 
  • Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer.
  • Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA.
  • His guidance and his wealth of regulatory experience in the cardio-renal area at the FDA will tremendously benefit our mission to bring ST-62516 to patients,” said Anna Kazanchyan, MD, Founder and CEO of Saghmos.
  • ST-62516 could benefit all PCI patients, not just those with comorbidities, to reduce the threat of AKI and MACKE after PCI.

Contract Logix Recognizes Trailblazers in Digital Contract Transformation (DCX), Announcing 2023 DCX Award Winners

Retrieved on: 
화요일, 3월 5, 2024
Hospital, Winners, Assistant, Marketing, Quality of life, Digital, Accountable care organization, Overalls, Risk, ACH, Medicare, DCX, Organization, Patient, Patent, Shirin David, CLM, Paralegal, Devlin, Software, Workflow, Nursing

LOWELL, Mass., March 5, 2024 /PRNewswire-PRWeb/ -- Contract Logix, a leading provider of data-driven contract management software, today announced the Winners, Runners-Up, and Finalists of its 2023 Digital Contract Transformation (DCX) Awards. These organizations and individuals were recognized for driving commitment to contract lifecycle management (CLM) and for evangelizing how DCX can have a significant positive impact on business processes, as well as improving collaboration, mitigating risk, increasing compliance, and finalizing business faster.

Key Points: 
  • Customer Awards Program Celebrates Individuals and Organizations Digitally Transforming Contract Lifecycle Management into an Intelligent, Automated, and Data-Driven Function
    LOWELL, Mass., March 5, 2024 /PRNewswire-PRWeb/ -- Contract Logix, a leading provider of data-driven contract management software , today announced the Winners, Runners-Up, and Finalists of its 2023 Digital Contract Transformation (DCX) Awards .
  • The Digital Contract Transformation Awards program is another way Contract Logix recognizes the innovative and creative ways our valued customers use our platform.
  • Digital Contract Transformation of the Year Award – Organizational Category:
    WINNER - American Choice Healthcare (ACH) for dramatic improvements in streamlining and automating its contracting processes to deliver improved reporting, visibility, and efficiency.
  • CovationBio's entire contract process is now automated across the entire lifecycle, from the contract request submission to third-party execution.

Tangibly Awarded IAM's IP Disruptors 2024 Award and Announces Major Product Updates to Help Accelerate Trade Secret Management in the Enterprise

Retrieved on: 
화요일, 2월 13, 2024
Research, IAM, AI, Patent, Shirin David, IP, Intellectual property, Negotiation, NDA, Partnership, Video game

SEATTLE, Feb. 13, 2024 /PRNewswire/ -- Tangibly, the leading AI powered trade secret management platform, is proud to announce that it has been awarded the prestigious IAM IP Disruptor 2024 award.

Key Points: 
  • SEATTLE, Feb. 13, 2024 /PRNewswire/ -- Tangibly, the leading AI powered trade secret management platform, is proud to announce that it has been awarded the prestigious IAM IP Disruptor 2024 award.
  • The award highlights Tangibly's contributions to transforming the landscape of IP management and protection of trade secrets through its innovative solutions.
  • This award confirms the importance of trade secrets and reinforces Tangibly's mission to help companies manage their trade secrets as business assets.
  • Seamlessly integrated into Tangibly's trade secret management platform, Patent X-Ray empowers legal teams and law firms to identify and document potential trade secrets associated with patents.

Ontra Celebrates One Million Documents; Adds GPT-4 to Industry-Leading Contract Automation Platform

Retrieved on: 
화요일, 2월 6, 2024
Intelligence, GM, SAN, Shirin David, PEI, Automation, Friction, Digital, OpenAI, Investment, Sales

SAN FRANCISCO, Feb. 6, 2024 /PRNewswire/ -- Ontra, the leader in AI-powered contract automation and intelligence, today celebrated its milestone achievement of processing over one million contracts for its customers, while concurrently announcing new GPT-4 enhancements to its Contract Automation platform.

Key Points: 
  • SAN FRANCISCO, Feb. 6, 2024 /PRNewswire/ -- Ontra, the leader in AI-powered contract automation and intelligence, today celebrated its milestone achievement of processing over one million contracts for its customers, while concurrently announcing new GPT-4 enhancements to its Contract Automation platform.
  • Contract Automation is also used by dozens of prominent investment banks and offered through partnerships with AM Law 100 firms and service providers.
  • Designed to help private capital markets firms accelerate the negotiation of key contracts and dealmaking, Ontra's Contract Automation offers an end-to-end platform solution that is powered by industry-leading AI.
  • "One million contracts processed marks a historic moment for Ontra, and it's just the beginning," said Frank Giovinazzo, Ontra's GM of Contract Automation.

Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

Retrieved on: 
금요일, 2월 2, 2024
Orbis, HC, JAMA, TGA, HSA, European, Shirin David, Immunotherapy, Trial of the century, Nasopharyngeal carcinoma, NPC, PFS, Clutch (eggs), Cisplatin, Patient, Safety, ASCO, New Drug Application, American Medical Association, Shanda, Progression-free survival, FDA, Marketing, OCE, Dor, Food, Society, Health Canada, Risk, Journal, Death, Health care, NDA, HKEX, Pharmaceutical industry

This NDA was submitted through Project Orbis, an initiative of the US Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE).

Key Points: 
  • This NDA was submitted through Project Orbis, an initiative of the US Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE).
  • At present, eight regulatory agencies have joined Project Orbis, including the FDA, the Australia Therapeutic Goods Administration (“TGA”), HSA, Health Canada (HC), the U.K.
  • Previously, two NDAs for toripalimab for the treatment of NPC had been submitted to the TGA through Project Orbis and were successfully accepted.
  • Junshi Biosciences will explore accelerated marketing opportunities in countries and regions where it is applicable.

Clark Street Capital Launches the Accelerated BAN, a new platform to sell loans in as little as 2 Weeks

Retrieved on: 
목요일, 1월 18, 2024
Professional Services, Other Professional Services, Finance, Consulting, Banking, Personal Finance, Clark Street, Database, C&I, Sales, RV, Shirin David, Retirement, Sale, BAN, SBA, Holiday, Auction

Clark Street specializes in negotiated sales with a fixed launch date, and a fixed indicative bid date.

Key Points: 
  • Clark Street specializes in negotiated sales with a fixed launch date, and a fixed indicative bid date.
  • After indicative bids, Clark Street can either proceed to a best-and-final bid or negotiate directly with a party or parties.
  • Recently, Clark Street completed its first Beta test, in which it successfully marketed a $2MM multi-family loan.
  • Clark Street Capital is a full-service bank advisory firm specializing in loan sales, loan due diligence and valuation and specialty asset management.

Diamond Sports Group Releases Cleansing Materials

Retrieved on: 
수요일, 1월 17, 2024
Entertainment, Communications, Sports, TV and Radio, General Sports, Media, Diamond, JPMorgan Chase, Creditor, Multimedia, Shirin David, Diamond Sports Group, RSA, Confidentiality, Bankruptcy, The Company, Cryptocurrency

Diamond Sports Group, LLC ("Diamond" or the "Company"), today issued the following updates.

Key Points: 
  • Diamond Sports Group, LLC ("Diamond" or the "Company"), today issued the following updates.
  • View the full release here: https://www.businesswire.com/news/home/20240116883620/en/
    In December 2023, Diamond entered into confidentiality agreements (the “NDAs”) with certain holders of its funded indebtedness (the “Creditors”) in connection with the Creditors’ evaluation of a potential alternative transaction involving Diamond.
  • Diamond is disclosing the Unaudited Financial Summary, the RSA, and the Settlement Term Sheet in satisfaction of its obligations under the NDAs.
  • Additional information regarding Diamond’s Chapter 11 cases, including court filings and information about the claims process are available at https://cases.ra.kroll.com/DSG .

Exro Releases Q1 2024 Letter to Shareholders

Retrieved on: 
월요일, 1월 15, 2024
ACT, Certification, Research, Social media, OEM, Traction, Uncertainty, Partnership, Shirin David, Electronics, Coil, UPS, Ecosystem, HB4, Public expenditure, Strategic planning, AB, TSX, F59, Pressure, Original equipment manufacturer, LINK, Lifting, Cell, Letter, Marketing, Innovation system, UL, Motivation, Renewable energy

CALGARY, AB, Jan. 15, 2024 /PRNewswire/ - Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro"), a leading clean-technology company that develops new generation power-control electronics that expand the capabilities of electric motors and batteries, is pleased to announce the release of a Q1 2024 letter to shareholders.

Key Points: 
  • CALGARY, AB, Jan. 15, 2024 /PRNewswire/ - Exro Technologies Inc. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro"), a leading clean-technology company that develops new generation power-control electronics that expand the capabilities of electric motors and batteries, is pleased to announce the release of a Q1 2024 letter to shareholders.
  • Indicated in our December shareholder letter and as tradition holds, this Q1 2024 shareholder letter outlines our strategic focus areas for 2024 and references notable strides completed over the past twelve months.
  • Exro recently held in-person management work outs to chart out the strategic plans for the 2024 launch and marketing of the E-Beam Axle program.
  • As we enter 2024 Exro continues to execute its capital markets strategy to ensure we are adequately funded to deliver to customers and shareholders.

FINSIGHT Group Inc. Calls on Q4 Inc. Shareholders to Vote AGAINST the Proposed Acquisition by Sumeru Equity Partners

Retrieved on: 
금요일, 1월 12, 2024
Special, Research, Face, Committee, Sale, Letter, Apathy, Growth, MIC, Revenue stream, Tax, NDA, Disclosure, Marketing, Arrangement, Shirin David, Frustration, Rolling, ARPC, NOT, Proxy, ALL, Fatigue, IPO, USD, Thoma Bravo, Negotiation, Security (finance)

NEW YORK, Jan. 12, 2024 (GLOBE NEWSWIRE) -- FINSIGHT Group Inc ("FINSIGHT"), a New York City based financial technology provider that beneficially owns over 2 million or approximately 5.6% of Q4’s outstanding shares and represents approximately 8.9% of the non-rolling shareholders, today called on its fellow Q4 Inc (“Q4” or the “Company”) shareholders to join FINSIGHT in voting AGAINST the Company’s proposed plan of arrangement to be acquired by Sumeru Equity Partners (“Sumeru”) (the “Arrangement”) at a special meeting of Q4 shareholders ("Special Meeting") currently scheduled for January 24, 2024. (All amounts in USD unless otherwise specified).

Key Points: 
  • The MIC disclosures and the perspectives of other shareholders shared with FINSIGHT, increased its conviction that the Arrangement should be opposed by all Q4 shareholders.
  • The consideration offered to Non-Rolling Shareholders by Sumeru Equity Partners, Q4 Management, and the other insiders is grossly inadequate.
  • FINSIGHT believes Non-Rolling Shareholders have a real and viable opportunity to vote down the Arrangement, given the concentration of long-term Non-Rolling Shareholders, and the exclusion of Rolling Shareholders from the ‘Majority of Minority’ vote.
  • Fellow shareholders, you do not have to accept this opportunistic value transfer from your pocket to that of the Rolling Shareholders and Sumeru.

NEO Battery Materials Files 9th Silicon Anode Patent for Major Manufacturing Innovation

Retrieved on: 
목요일, 1월 11, 2024
Silicon, OEM, Shirin David, KIPO, NDA, Quality control, NEO, Patent, Silicone, Particle size, Electric battery

TORONTO, Jan. 11, 2024 (GLOBE NEWSWIRE) -- January 11, 2024 – (TSXV: NBM) (OTCQB: NBMFF)

Key Points: 
  • TORONTO, Jan. 11, 2024 (GLOBE NEWSWIRE) -- January 11, 2024 – (TSXV: NBM) (OTCQB: NBMFF)
    6 NDAs Secured with Global Chemical Material, Automotive OEM, and Battery Cell Manufacturers
    NEO Battery Materials Ltd. (“NEO” or the “Company”), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that the Company has filed the 9th patent regarding a significant development in the silicon anode manufacturing process.
  • NEO Battery Materials has submitted the 9th patent entitled Silicone composite manufacturing method to the Korean Intellectual Property Office (KIPO).
  • This patent protects a significant innovation in the manufacturing process of NEO’s proprietary silicon anode materials, NBMSiDE®.
  • We aim to create comprehensive protection that precludes any replication attempt from final silicon anode products, nanocoating materials, and value-added projects.